Scholar Rock price target raised to $47 from $40 at Wedbush

Wedbush raised the firm’s price target on Scholar Rock (SRRK) to $47 from $40 and keeps an Outperform rating on the shares. Biohaven’s (BHVN) trial miss leaves Scholar Rock’s apitegromab as the only agent in the class likely to gain approval in the near-term in spinal muscular atrophy, the analyst tells investors in a research note. The firm now anticipates greater market penetration with Scholar Rock’s treatment with a launch possible as early as Q4 of 2025.